Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Apr 14, 2024 4:42pm
220 Views
Post# 35988399

New things? Up & coming.

New things? Up & coming.

I enjoy reasonable questions.
such as when will we receive update & panc trail ?
That m BTW could become the billion $ question.
Reading the published information & reading between the lines, the best known information says plans to further detail the process will be first half of this year.
Meaning between now & June.
The corporate presentation goes on to say they will define the trial parameters, with enrolling starting early 2025.
My question which we don't know. What is the hold up with announcements regarding the pancreatic cancer phase 3 , registration trial?
The MBc has not said formally, but observations would indicate they are waiting to see results from overall survival....before a formal business deal.
The recent FDA filing for a meeting to discuss parameters is great progress.
Having a clear definition of acceptable biomarkers & other finer details, will give Onc a stronger ( more solid with less doubt), ability to negotiate a business deal.
Reading between the lines, my guess/ opinion, they have been asked by potential partners to hone in ine the trial details, then we will be happier to commit some $$.
The MBc fda meeting came out if the blue. I expect to see the same with the pancreatic cancer progress.
An actual date? I'm not sure what the wait is, if we knew that it would be easier to guess an announcement date.
Again best data available says first half of this year.
For those who have been around for years, another month ir two is short term.
For those looking for a quick jump, might seem too long.
Side note. Seeing the FDA verbiage " up to 70 days to respond etc", shows the snails pace Onc is working within.
other side, along that line. " unto 70 days" does not mean 70 days.
Could be anytime..up to & including 70 days.
watching that event unfold will be an interesting study of FDA process & bureaucracy.
The inplace " fast track approval" by its published definition, says quicker attention for meetings & such.
Moving the lens further out.
lots of things in process right now.
waiting for results/ updates on 3 oF the Gobblet trials. Waiting to start enrolment in the newest $5million grant G.I. Trial arm.
negotiations, ongoing.
They must come up with a significant $$ influx soon.
The opposites are there.
i expect something before the AGm.


 

 

<< Previous
Bullboard Posts
Next >>